Open AccessCost-utility of erlotinib combined with bevacizumab versus bevacizumab alone after completion of chemotherapy with bevacizumab for first-line treatment of advanced non-small-cell lung cancer
Author(s) -
Shuwen Yu
Publication year - 2017
Publication title -
journal of chinese pharmaceutical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.138
H-Index - 12
ISSN - 1003-1057
DOI - 10.5246/jcps.2017.06.049
Subject(s) - bevacizumab , erlotinib , medicine , oncology , lung cancer , chemotherapy , cancer , epidermal growth factor receptor